injectable glp-1 GLP-1s GLP-1 overdoses have been skyrocketing,
Description
New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases.
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Not for human or veterinary use
What I'm watching: The Alzheimer's Association listed GLP-1 research as a top 10 development to watch in 2026
Great shipping and support, but hidden pricing traps and a 2-month lock-in.
Learn more about our San Diego Prescription Weight Loss Program.
